June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
November 2008 in “Journal of Generic Medicines” The document updates on EU legal changes, including pharmaceutical patents, class actions in Italy, and various drug-related rulings.
Combining bromelain with finasteride improves hair regrowth and reduces inflammation in alopecia.
12 citations
,
January 2024 in “Journal of the American Academy of Dermatology” 59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
69 citations
,
February 2021 in “PLoS Computational Biology” Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.
March 2026 in “Journal of the American Academy of Dermatology” The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
June 2026 in “Frontiers in Oncology” Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.
7 citations
,
January 2012 in “PubMed” Azelaic acid and finasteride can help preserve skin flaps after surgery by increasing BCL-2 protein and decreasing bax protein.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
August 2020 in “International Journal of Dermatology and Venereology” PRP is an effective and safe treatment for hair loss in women.
5 citations
,
October 2024 in “International Journal of Molecular Sciences” Piperonylic acid may help hair growth and treat hair loss.
January 2008 in “Journal of Medicinal Chemistry” Finasteride may cause sexual and psychological side effects by affecting an enzyme related to epinephrine.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
January 2026 in “JAAD International” Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
21 citations
,
July 2011 in “Journal of the American Academy of Dermatology” A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
20 citations
,
July 2013 in “PLoS ONE” Targeting EGFR may help reduce hair loss from chemotherapy.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
Eriocitrin and silymarin might be effective for hair loss treatment and need more research.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Potential compounds may inhibit hair loss by targeting a non-androgen pathway.
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
January 2004 in “Indian Journal of Nephrology” April 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Chronic use of 1 mg/day finasteride for hair loss may delay prostate cancer diagnosis by lowering PSA levels.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.